Roivant Sciences (NASDAQ:ROIV) Insider Frank Torti Sells 1,012,610 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,012,610 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $27.15, for a total transaction of $27,492,361.50. Following the transaction, the insider directly owned 13,736,547 shares of the company’s stock, valued at $372,947,251.05. This represents a 6.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Frank Torti also recently made the following trade(s):

• On Thursday, February 19th, Frank Torti sold 1,400,000 shares of Roivant Sciences stock. The stock was sold at an average price of $27.42, for a total value of $38,388,000.00.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The stock was sold at an average price of $27.51, for a total value of $16,159,098.90.

Roivant Sciences Stock Up 2.2%

ROIV stock opened at $27.76 on Tuesday. The business has a 50 day moving average of $23.44 and a 200 day moving average of $19.07. The firm has a market cap of $19.87 billion, a PE ratio of -23.73 and a beta of 1.22. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $27.94.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently made changes to their positions in the stock. Penn Davis Mcfarland Inc. raised its stake in Roivant Sciences by 10.1% during the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after acquiring an additional 170,456 shares during the period. Valeo Financial Advisors LLC bought a new position in shares of Roivant Sciences in the second quarter worth approximately $1,145,000. IFG Advisory LLC purchased a new stake in shares of Roivant Sciences in the second quarter worth $255,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $3,064,000. Finally, Franklin Resources Inc. bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $997,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ROIV shares. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Roivant Sciences in a research note on Monday, February 9th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Leerink Partners upped their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Citigroup increased their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, Guggenheim raised their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.